Merck & Co., Inc. and Subsidiaries Years Ended December 31
Percentage Change from Preceding Year
($ in millions except per share amounts)
2006(1)
2005(2)
2004(3)
2006
2005
Sales
$
22,636.0
$
22,011.9
$
22,972.8
+3
%
-4
%
Net income
4,433.8
4,631.3
5,830.1
-4
%
-21
%
Earnings per common share assuming dilution
$
2.03
$
2.10
$
2.62
-3
%
-20
%
Cash dividends paid per common share Average common shares outstanding
$
1.52
$
1.52
$
1.49
-
+2
%
assuming dilution (millions)
2,187.7
2,200.4
2,226.4
Total assets
44,569.8
44,845.8
42,572.8
Net cash flows provided by operating activities
6,765.2
7,608.5
8,799.1
Capital expenditures
980.2
1,402.7
1,726.1
Net income as a % of average total assets
9.9
%
10.6
%
14.0
%
Number of stockholders of record
184,200
198,200
216,100
Number of employees
60,000
61,500
62,600
(1) Amounts for 2006 include the impact of restructuring actions, acquired research expenses associated with acquisitions made during the year, additional Vioxx legal defense costs and the incremental impact of expensing stock options.
(2) Amounts for 2005 include the impact of the net tax charge primarily associated with the AJCA repatriation, restructuring actions and additional Vioxx legal defense costs.
(3) Amounts for 2004 include the impact of the withdrawal of Vioxx, Vioxx legal defense costs and restructuring actions.
